Literature DB >> 12943678

A novel human glycosyltransferase: primary structure and characterization of the gene and transcripts.

Taisto Y K Heinonen1, Leena Pasternack, Katri Lindfors, Christelle Breton, Louis N Gastinel, Markku Mäki, Heikki Kainulainen.   

Abstract

We report the identification and primary structure of a novel human glycosyltransferase, B3GTL (beta3-glycosyltransferase-like). The 498 residue protein consists of a short cytoplasmic N-terminal "tail" (residues 1-4), a single transmembrane domain with type II topology (residues 5-28), a "stem" region (residues 29-260), and a catalytic domain (residues 261-498). The genomes of Anopheles gambiae, Drosophila melanogaster, and Caenorhabditis elegans encode potential orthologs which share 31-39% sequence identity with B3GTL, as well as the following features: a conserved catalytic domain containing a triple aspartate motif (DDD) at its core, a conserved pattern of cysteine residues, a C-terminal KDEL-like motif, and conserved residues and motifs that affiliate this novel group with a family of beta3-glycosyltransferases (GT31 in the CAZY classification). The B3GTL gene lacks canonical TATA and CAAT boxes and contains three functional polyadenylation sites. It is transcribed in a wide range of tissues and in TGF-beta-treated T84 epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12943678     DOI: 10.1016/s0006-291x(03)01540-7

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Mutation analysis of B3GALTL in Peters Plus syndrome.

Authors:  Linda M Reis; Rebecca C Tyler; Omar Abdul-Rahman; Pamela Trapane; Robert Wallerstein; Diane Broome; Jodi Hoffman; Aneal Khan; Christina Paradiso; Nitin Ron; Amanda Bergner; Elena V Semina
Journal:  Am J Med Genet A       Date:  2008-10-15       Impact factor: 2.802

2.  Peters Plus syndrome is caused by mutations in B3GALTL, a putative glycosyltransferase.

Authors:  Saskia A J Lesnik Oberstein; Marjolein Kriek; Stefan J White; Margot E Kalf; Karoly Szuhai; Johan T den Dunnen; Martijn H Breuning; Raoul C M Hennekam
Journal:  Am J Hum Genet       Date:  2006-07-19       Impact factor: 11.025

Review 3.  Cardiac complications of congenital disorders of glycosylation (CDG): a systematic review of the literature.

Authors:  D Marques-da-Silva; R Francisco; D Webster; V Dos Reis Ferreira; J Jaeken; T Pulinilkunnil
Journal:  J Inherit Metab Dis       Date:  2017-07-19       Impact factor: 4.982

4.  A 781-kb deletion of 13q12.3 in a patient with Peters plus syndrome.

Authors:  Chad R Haldeman-Englert; Taiyabah Naeem; Elizabeth A Geiger; Ashley Warnock; Holly Feret; Melissa Ciano; Stefanie L Davidson; Matthew A Deardorff; Elaine H Zackai; Tamim H Shaikh
Journal:  Am J Med Genet A       Date:  2009-08       Impact factor: 2.802

5.  Association of beta-1,3-N-acetylglucosaminyltransferase 1 and beta-1,4-galactosyltransferase 1, trans-Golgi enzymes involved in coupled poly-N-acetyllactosamine synthesis.

Authors:  Peter L Lee; Jennifer J Kohler; Suzanne R Pfeffer
Journal:  Glycobiology       Date:  2009-03-03       Impact factor: 4.313

6.  Functional characterization of zebrafish orthologs of the human Beta 3-Glucosyltransferase B3GLCT gene mutated in Peters Plus Syndrome.

Authors:  Eric Weh; Hideyuki Takeuchi; Sanaa Muheisen; Robert S Haltiwanger; Elena V Semina
Journal:  PLoS One       Date:  2017-09-19       Impact factor: 3.240

7.  Gene expression in TGFbeta-induced epithelial cell differentiation in a three-dimensional intestinal epithelial cell differentiation model.

Authors:  Kati M Juuti-Uusitalo; Katri Kaukinen; Markku Mäki; Jarno Tuimala; Heikki Kainulainen
Journal:  BMC Genomics       Date:  2006-10-31       Impact factor: 3.969

8.  Overexpression of GLT1D1 induces immunosuppression through glycosylation of PD-L1 and predicts poor prognosis in B-cell lymphoma.

Authors:  Xiaoxia Liu; Yanyu Zhang; Yi Han; Wenhua Lu; Jing Yang; Jingyu Tian; Peng Sun; Tiantian Yu; Yumin Hu; Hui Zhang; Peng Huang; Panpan Liu
Journal:  Mol Oncol       Date:  2020-04-13       Impact factor: 6.603

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.